These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 27456948)

  • 21. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas.
    Schalper KA; Velcheti V; Carvajal D; Wimberly H; Brown J; Pusztai L; Rimm DL
    Clin Cancer Res; 2014 May; 20(10):2773-82. PubMed ID: 24647569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune characterization of breast cancer metastases: prognostic implications.
    Dieci MV; Tsvetkova V; Orvieto E; Piacentini F; Ficarra G; Griguolo G; Miglietta F; Giarratano T; Omarini C; Bonaguro S; Cappellesso R; Aliberti C; Vernaci G; Giorgi CA; Faggioni G; Tasca G; Conte P; Guarneri V
    Breast Cancer Res; 2018 Jun; 20(1):62. PubMed ID: 29929548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lymphocyte-activating gene-3 expression is associated with tumor-infiltrating lymphocyte levels in HER2-positive breast cancers.
    Lee S; Kim JY; Lee SJ; Kwon SW; Jung HJ; Jung SJ; Kim KB; Choi KU; Lee CH; Huh GY; Kim A
    Medicine (Baltimore); 2021 Dec; 100(50):e28057. PubMed ID: 34918659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
    Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
    Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer.
    Song IH; Heo SH; Bang WS; Park HS; Park IA; Kim YA; Park SY; Roh J; Gong G; Lee HJ
    Cancer Res Treat; 2017 Apr; 49(2):399-407. PubMed ID: 27488875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy.
    Montagna E; Vingiani A; Maisonneuve P; Cancello G; Contaldo F; Pruneri G; Colleoni M
    Breast; 2017 Aug; 34():83-88. PubMed ID: 28544923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer.
    Kochi M; Iwamoto T; Niikura N; Bianchini G; Masuda S; Mizoo T; Nogami T; Shien T; Motoki T; Taira N; Tokuda Y; Doihara H; Matsuoka J; Fujiwara T
    Breast Cancer Res Treat; 2018 Jan; 167(1):39-47. PubMed ID: 28905250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.
    Cimino-Mathews A; Ye X; Meeker A; Argani P; Emens LA
    Hum Pathol; 2013 Oct; 44(10):2055-63. PubMed ID: 23701942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up.
    Lundgren C; Bendahl PO; Ekholm M; Fernö M; Forsare C; Krüger U; Nordenskjöld B; Stål O; Rydén L
    Breast Cancer Res; 2020 Dec; 22(1):140. PubMed ID: 33357231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer.
    Ingold Heppner B; Untch M; Denkert C; Pfitzner BM; Lederer B; Schmitt W; Eidtmann H; Fasching PA; Tesch H; Solbach C; Rezai M; Zahm DM; Holms F; Glados M; Krabisch P; Heck E; Ober A; Lorenz P; Diebold K; Habeck JO; Loibl S
    Clin Cancer Res; 2016 Dec; 22(23):5747-5754. PubMed ID: 27189162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy.
    Sinn BV; Weber KE; Schmitt WD; Fasching PA; Symmans WF; Blohmer JU; Karn T; Taube ET; Klauschen F; Marmé F; Schem C; Stickeler E; Ataseven B; Huober J; von Minckwitz G; Seliger B; Denkert C; Loibl S
    Breast Cancer Res; 2019 Dec; 21(1):142. PubMed ID: 31829264
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers.
    Tsang JY; Hui SW; Ni YB; Chan SK; Yamaguchi R; Kwong A; Law BK; Tse GM
    Breast Cancer Res Treat; 2014 Jan; 143(1):1-9. PubMed ID: 24272079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer.
    Criscitiello C; Bagnardi V; Pruneri G; Vingiani A; Esposito A; Rotmensz N; Curigliano G
    Eur J Cancer; 2017 Dec; 87():164-171. PubMed ID: 29154173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
    Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
    Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor-infiltrating lymphocytes are associated with β-catenin overexpression in breast cancer.
    Ma X; Zhao X; Yan W; Yang J; Zhao X; Zhang H; Hui Y; Zhang S
    Cancer Biomark; 2018 Feb; 21(3):639-650. PubMed ID: 29286921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
    Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
    Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes.
    Kim JY; Heo SH; Choi SK; Song IH; Park IA; Kim YA; Park HS; Park SY; Bang WS; Gong G; Lee HJ
    Virchows Arch; 2017 Apr; 470(4):381-389. PubMed ID: 28185053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathological and prognostic significance of FOXP3+ tumor infiltrating lymphocytes in patients with breast cancer: a meta-analysis.
    Jiang D; Gao Z; Cai Z; Wang M; He J
    BMC Cancer; 2015 Oct; 15():727. PubMed ID: 26475790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Importance of CD45RO+ tumor-infiltrating lymphocytes in post-operative survival of breast cancer patients.
    Ahmadvand S; Faghih Z; Montazer M; Safaei A; Mokhtari M; Jafari P; Talei AR; Tahmasebi S; Ghaderi A
    Cell Oncol (Dordr); 2019 Jun; 42(3):343-356. PubMed ID: 30825183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.